ES2596855T3 - Inducción de tolerancia mucosa a antígenos - Google Patents

Inducción de tolerancia mucosa a antígenos Download PDF

Info

Publication number
ES2596855T3
ES2596855T3 ES06830192.8T ES06830192T ES2596855T3 ES 2596855 T3 ES2596855 T3 ES 2596855T3 ES 06830192 T ES06830192 T ES 06830192T ES 2596855 T3 ES2596855 T3 ES 2596855T3
Authority
ES
Spain
Prior art keywords
acid
ova
microorganism
autoimmune
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06830192.8T
Other languages
English (en)
Inventor
Pieter Rottiers
Veerle Snoeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intrexon Actobiotics NV
Original Assignee
Intrexon Actobiotics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Actobiotics NV filed Critical Intrexon Actobiotics NV
Application granted granted Critical
Publication of ES2596855T3 publication Critical patent/ES2596855T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/50—Feeding-stuffs specially adapted for particular animals for rodents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Animal Husbandry (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)

Abstract

Una combinación que comprende un microorganismo secretor de IL-10 y un alérgeno, aloantígeno, antígeno propio o autoantígeno para su uso en la inducción de tolerancia inmunitaria o para su uso en el tratamiento de una enfermedad elegida del grupo que consiste en una reacción alérgica que incluye alergia alimentaria, enfermedad celíaca, asma alérgica, uveítis autoinmunitaria, tiroiditis autoinmunitaria, miastenia gravis autoinmunitaria, artritis reumatoide, diabetes tipo I, esclerosis múltiple, enfermedad de injerto contra huésped, inmunoactivación de producto terapéutico, y producción de anticuerpos contra el Factor VIII no endógeno, en un mamífero.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
vida restante del mamífero); por ejemplo desde aproximadamente (2 o 3 o 5 días, 1 o 2 semanas, o 1 mes) hacia arriba y/o por ejemplo hasta aproximadamente (5 años, 1 año, 6 meses, 1 mes, 1 semana, o 3 o 5 días). Es típica la administración de la dosis de mantenimiento diaria durante de aproximadamente 3 a aproximadamente 5 días o durante de aproximadamente 1 semana a aproximadamente 1 año. Otros constituyentes de las formulaciones
5 líquidas pueden incluir conservantes, sales inorgánicas, ácidos, bases, tampones, nutrientes, vitaminas u otros productos farmacéuticos.
El microorganismo que secreta el compuesto inmunomodulador y/o el antígeno puede administrarse en una dosis de al menos 104 unidades formadoras de colonias (ufc) a 1012 ufc al día, preferiblemente entre 106 ufc y 1012 ufc al día,
10 lo más preferiblemente entre 109 ufc y 1012 ufc al día. Según el método descrito en Steidler y col. (Science 2000), el compuesto inmunomodulador de por ejemplo de 109 ufc se secreta hasta de al menos 1 ng a 100 ng. A través de ELISA, conocido por un experto en la técnica, el antígeno de, por ejemplo, de 109 ufc se secreta hasta de al menos 1 ng a 100 ng; el experto en la técnica puede calcular el intervalo de secreción de compuesto inmunomodulador y/o antígeno en relación con cualquier otra dosis de ufc.
15 El antígeno puede administrarse en una dosis que induce una respuesta a baja dosis. Preferiblemente, dicho antígeno se administra en una dosis de al menos 10 fg a 100 µg al día, preferiblemente entre 1 pg y 100 µg al día, lo más preferiblemente entre 1 ng y 100 µg al día.
20 El compuesto inmunomodulador de la invención puede administrarse en una dosis de al menos 10 fg a 100 µg al día, preferiblemente entre 1 pg y 100 µg al día, mucho más preferiblemente entre 1 ng y 100 µg al día.
Preferiblemente, los compuestos o la composición se proporcionan en una forma farmacéutica unitaria, por ejemplo un comprimido, una solución, una cápsula o una dosis de aerosol medida, de modo que se administra una dosis 25 única al sujeto, por ejemplo un paciente.
Dependiendo del modo de administración, por ejemplo oral, o cualquiera de los descritos anteriormente, el experto en la técnica conoce cómo definir o calcular la dosis real que va a administrarse a un paciente. El experto en la técnica tendrá conocimientos sobre cómo ajustar las dosis dependiendo del paciente, el microorganismo, el vector,
30 etc.
Los compuestos de la presente invención también pueden tomar la forma de una sal, hidrato, solvato o metabolito farmacológicamente aceptable. Las sales farmacológicamente aceptables incluyen sales básicas de ácidos orgánicos e inorgánicos, incluyendo, pero sin limitación, ácido clorhídrico, ácido bromhídrico, ácido sulfúrico, ácido 35 fosfórico, ácido nítrico, ácido metanosulfónico, ácido etanosulfónico, ácido p-toluenosulfónico, ácido naftalenosulfónico, ácido málico, ácido acético, ácido oxálico, ácido tartárico, ácido cítrico, ácido láctico, ácido fumárico, ácido succínico, ácido maleico, ácido salicílico, ácido benzoico, ácido fenilacético, ácido mandélico y similares. Cuando los compuestos de la invención incluyen una función ácida, tal como un grupo carboxilo, entonces los expertos en la técnica conocen bien pares catiónicos farmacéuticamente aceptables para el grupo carboxilo e
40 incluyen cationes alcalinos, alcalinotérreos, de amonio, de amonio cuaternario y similares.
El microorganismo puede ser cualquier microorganismo, incluyendo bacterias, levaduras u hongos, adecuados para administración mucosa. Preferiblemente, dicho microorganismo es un microorganismo no patógeno, incluso más preferiblemente dicho microorganismo es un microorganismo probiótico. El experto en la técnica conoce organismos 45 probióticos. Los organismos probióticos incluyen, pero sin limitación, bacterias tales como Lactobacillus sp., Lactococcus sp., y levaduras tales como Saccharomyces cerevisiae subspecies boulardii. Preferiblemente, dicha bacteria es una bacteria de ácido láctico; incluso más preferiblemente, dicha bacteria de ácido láctico se elige entre el grupo que consiste en Lactobacillus, Leuconostoc, Pediococcus, Lactococcus, Streptococcus, Aerococcus, Carnobacterium, Enterococcus, Oenococcus, Teragenococcus, Vagococcus y Weisella. En una realización preferida
50 adicional, dicho microorganismo es Lactococcus lactis. En otras realización preferida, dicho microorganismo es Saccharomyces cerevisiae.
En una realización preferida, la citocina inmunosupresora se combina con anticuerpos antagonizantes contra citocinas inmunoinductoras, tales como anti-IL-2, anti-IL-12 y/o anti-IFNγ; y moléculas coestimuladoras, tales como 55 anti-CD40L y anti-CD3. Como alternativa, pueden administrarse compuestos que estimulan la producción de las citocinas inmunosupresoras, tales como subunidad B de la toxina del cólera; y moléculas que estimulan la función de linfocitos T reguladores, tales como agonistas de CTLA-4 e ICOS. Como se ha descrito anteriormente, preferiblemente, dicho microorganismo es un microorganismo no patógeno, incluso más preferiblemente es un microorganismo probiótico. El experto en la técnica conoce organismos probióticos, e incluyen, pero sin limitación,
9
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
Dos modelos de ratón de asma alérgica que imita a la enfermedad humana son el modelo de alérgeno Ova y el modelo SCID humanizado.
El modelo de alérgeno Ova
5 Se exponen mediante inhalación ratones sensibilizados a OVA con aerosol de OVA que conduce a inflamación eosinofílica de las vías respiratorias dependiente de citocinas Th2, hiperreactividad bronquial y producción de IgE, hallazgos ampliamente característicos del asma alérgica humana (Brusselle, 1994, Clin Exp Allergy 24: 73; Kips y col. 1996, Am J Respir Crit Care Med 153: 535; Brusselle y col. 1995, Am J Respir Cell Mol Biol 12: 254).
10
Bacterias
Se usa la cepa MG1363 de L. lactis a lo largo de todo este estudio. Se cultivan las bacterias en medio GM17, es decir, M17 (Difco Laboratories, Detroit, MI) complementado con glucosa al 0,5 %. Se almacenan las suspensiones
15 madre de todas las cepas a -20 ºC en glicerol al 50 % en GM17. Para inoculaciones intragástricas, se diluyen las suspensiones madre 200 veces en GM17 nuevo y se incuban a 30 ºC. Alcanzaron una densidad de saturación de 2 x 109 unidades formadoras de colonias (UFC) por ml en el plazo de 16 horas. Se recogen las bacterias mediante centrifugación y se concentran 10 veces en medio BM9. Para el tratamiento, cada ratón recibe 100 µl de esta suspensión diariamente mediante catéter intragástrico.
20
Plásmidos
Se recupera la secuencia de ARNm que codifica para ovoalbúmina de Gallus gallus de Genbank (número de registro AY223553). Se aísla ARN total de útero de pollo y se sintetiza ADNc usando 2 µg de ARN total, cebadores de oligo
25 dT2 µM (Promega Corporation Benelux, Leiden, Países Bajos), DTT 0,01 mM (Sigma-Aldrich, Zwijndrecht, Países Bajos), dNTP 0,5 mM (Invitrogen, Merelbeke, Bélgica), 20 U de Rnasin (Promega Incorporation Benelux) y 100 U de transcriptasa inversa Superscript II (Invitrogen) en un volumen de 25 µl. Se amplifica el fragmento de ADNc de OVA mediante reacción en cadena de la polimerasa (PCR) usando las siguientes condiciones: 94 ºC durante 2 min seguido de 30 ciclos a 94 ºC durante 45 segundos, 62 ºC durante 30 segundos y 72 ºC durante 90 segundos, con los
30 siguientes cebadores directo e inverso 5'-GGCTCCATCGGTGCAGCAAGCATGGAATT-3' y 5'-ACTAGTTAAGGGGAAAC-ACATCTGCCAAAGAAGAGAA-3'.
Se fusiona el fragmento amplificado a la señal de secreción Usp45 del vector pT1NX resistente a eritromicina, en el 35 sentido de 3' del promotor P1 de lactococos.
Las cepas MG1363 transformadas con plásmidos que portan IL-10 murina y ADNc de OVA se designan LL-IL10 y LL-OVA. LL-pT1NX, que es MG1363 que contiene el vector vacío pT1NX, sirven como control.
40 Cuantificación de OVA
Se determina OVA a partir de LL-OVA usando un ensayo inmunoabsorbente ligado a enzimas (ELISA) específico de OVA desarrollado en el laboratorio. También se evalúa la producción de las proteínas recombinantes mediante análisis de transferencia de tipo Western.
45
El modelo de alérgeno OVA
Ratones
50 Se adquieren ratones BALB/c (de 6 a 8 semanas de edad) de Charles River Laboratories (Calco, Italia). Se mantienen los ratones en condiciones libres de patógenos específicos.
Inmunización de los ratones
55 Se inmunizan los ratones por vía i.p. con 2 µg de OVA (calidad V; Sigma-Aldrich) en 2 mg de hidróxido de aluminio (alumbre). Se repite esta inmunización tras un intervalo de 10 días (en los días 0 y 10). Los ratones control reciben una inyección de solución salina en lugar de la disolución de OVA/alumbre. Siete días tras la inmunización, los ratones sensibilizados inhalan una disolución aerosolizada de OVA al 3 % disuelta en PBS durante 10 min. Se realiza la inhalación de OVA durante 3 días en una fila (días 18, 19, y 20). Los ratones control inhalan PBS solo en
18
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30

Claims (1)

  1. imagen1
    imagen2
    imagen3
ES06830192.8T 2005-11-29 2006-11-29 Inducción de tolerancia mucosa a antígenos Active ES2596855T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05111467 2005-11-29
EP05111467 2005-11-29
PCT/EP2006/069062 WO2007063075A1 (en) 2005-11-29 2006-11-29 Induction of mucosal tolerance to antigens

Publications (1)

Publication Number Publication Date
ES2596855T3 true ES2596855T3 (es) 2017-01-12

Family

ID=37889980

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09169276T Active ES2405552T3 (es) 2005-11-29 2006-11-29 Inducción de tolerancia mucosa a antiantígenos de células beta de islotes pancreáticos
ES06830192.8T Active ES2596855T3 (es) 2005-11-29 2006-11-29 Inducción de tolerancia mucosa a antígenos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES09169276T Active ES2405552T3 (es) 2005-11-29 2006-11-29 Inducción de tolerancia mucosa a antiantígenos de células beta de islotes pancreáticos

Country Status (13)

Country Link
US (5) US8748126B2 (es)
EP (3) EP1957100B1 (es)
JP (2) JP5410759B2 (es)
CN (1) CN101316611B (es)
AU (1) AU2006319216B2 (es)
BR (1) BRPI0619206A2 (es)
CA (1) CA2631598C (es)
DK (1) DK2119450T3 (es)
ES (2) ES2405552T3 (es)
HK (1) HK1231371A1 (es)
PT (1) PT2119450E (es)
RU (1) RU2420569C2 (es)
WO (1) WO2007063075A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
ES2405552T3 (es) 2005-11-29 2013-05-31 Actogenix N.V. Inducción de tolerancia mucosa a antiantígenos de células beta de islotes pancreáticos
WO2007070660A2 (en) 2005-12-13 2007-06-21 President And Fellows Of Harvard College Scaffolds for cell transplantation
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
CA2672229A1 (en) * 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
WO2008090223A2 (en) 2007-01-25 2008-07-31 Actogenix N.V. Treatment of immune disease by mucosal delivery of antigens using genetically modified lactobacillus
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
FI20075539L (fi) * 2007-07-12 2009-01-13 Valio Oy Maitohappobakteerit, joilla on proinflammatorisia ominaisuuksia
CN102006891B (zh) 2008-02-13 2017-04-26 哈佛学院董事会 连续的细胞程序化装置
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
EP2331124A1 (en) 2008-08-15 2011-06-15 Circassia Limited T-cell antigen peptide from allergen for stimulation of il-10 production
ES2378870T5 (es) 2008-08-15 2016-02-03 Circassia Limited Vacuna que comprende péptidos Amb a 1 para uso en el tratamiento de alergia a ambrosía
WO2010056143A1 (en) * 2008-11-13 2010-05-20 Instituto De Medicina Molecular The use of adjuvant to facilitate the induction of immune tolerance
HRP20150317T1 (hr) 2009-02-05 2015-04-24 Circassia Limited Peptidi trave za cjepivo
US10617640B2 (en) 2009-07-07 2020-04-14 The Research Foundation For The State University Of New York Phosphoserine containing compositions for immune tolerance induction
EP3058953A1 (en) * 2009-07-07 2016-08-24 The Research Foundation Of State University Of New York Lipidic compositions for induction of immune tolerance
AU2010278702C1 (en) 2009-07-31 2016-07-14 Forsyth Dental Infirmary For Children Programming of cells for tolerogenic therapies
US20110081320A1 (en) * 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
MX337716B (es) 2010-03-10 2016-03-16 Kaneka Corp Preparacion que contiene bacteria de acido lactico.
WO2011150235A1 (en) * 2010-05-27 2011-12-01 Allertein Therapeutics, Llc Methods and reagents for treating autoimmune disorders and/or graft rejection
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN107648668B (zh) 2010-10-06 2021-06-18 哈佛学院董事会 用于基于材料的细胞疗法的可注射的成孔水凝胶
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
US10045947B2 (en) 2011-04-28 2018-08-14 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
EP2714073B1 (en) 2011-06-03 2021-03-10 President and Fellows of Harvard College In situ antigen-generating cancer vaccine
HUE038336T2 (hu) 2011-09-23 2018-10-29 Intrexon Actobiotics Nv Módosított gram-pozitív baktériumok és alkalmazásaik
JP6117212B2 (ja) 2011-09-23 2017-04-19 イントレクソン・アクトバイオテイクス・エヌブイＩｎｔｒｅｘｏｎ Ａｃｔｏｂｉｏｔｉｃｓ ＮＶ 改変されたグラム陽性菌及びその使用
US9375468B2 (en) * 2012-02-08 2016-06-28 Premune Ab Prevention of inflammatory disorders in domestic non-human mammals
DK2838515T3 (da) 2012-04-16 2020-02-24 Harvard College Mesoporøse siliciumdioxidsammensætninger til modulering af immunresponser
BR112014029417B1 (pt) * 2012-05-25 2023-03-07 Cellectis Método ex vivo para a preparação de células t para imunoterapia
JP6219728B2 (ja) * 2014-01-15 2017-10-25 キッコーマン株式会社 Ｆｏｘｐ３陽性制御性Ｔ細胞とＩＦＮ−γ産生ＩＬ−１０産生Ｔ細胞誘導を指標とした、経口免疫寛容物質スクリーニング方法及び経口免疫寛容増強組成物
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
SG11201606761RA (en) * 2014-02-21 2016-09-29 Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
EP2989904A1 (en) * 2014-07-29 2016-03-02 Heinrich-Heine-Universität Induction of immunological tolerance using yeast
KR101662898B1 (ko) * 2014-09-02 2016-10-06 서울대학교산학협력단 점막점착성 고분자 및 이의 용도
US10696974B2 (en) 2014-12-23 2020-06-30 Ilya Pharma Ab Methods for wound healing
EP3247384B1 (en) * 2015-01-14 2023-10-04 The Regents of the University of Colorado, a body corporate In vitro method of diagnosis of type 1 diabetes with insulin mimotopes
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
WO2016164705A1 (en) 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
EP3081227A1 (en) * 2015-04-15 2016-10-19 Institut National De La Recherche Agronomique Lactococcus lactis producing tslp or il-25 and their uses as probiotics and therapeutics
WO2017062175A1 (en) 2015-10-06 2017-04-13 Albert Einstein College Of Medicine, Inc. Microbial hyperswarmers and uses thereof
US11752238B2 (en) 2016-02-06 2023-09-12 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
CN109789092A (zh) 2016-07-13 2019-05-21 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
IL264557B2 (en) 2016-08-02 2024-01-01 Harvard College Biological agents for regulating immune responses
CN118813511A (zh) 2016-09-02 2024-10-22 英特瑞克斯顿阿克图比奥帝克斯有限公司 稳定表达il-10和胰岛素的遗传修饰的细菌
RU2021135949A (ru) 2016-09-13 2022-04-14 Интрексон Актобиотикс Н.В. Мукоадгезивный микроорганизм
CN108114272B (zh) * 2016-11-28 2026-01-06 上海市第五人民医院 一种构建哮喘免疫耐受模型的方法
WO2019067871A2 (en) * 2017-09-29 2019-04-04 Nantcell, Inc. ANTIGENIC PROTEINS AND ASSOCIATED METHODS
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
JP2020000033A (ja) * 2018-06-26 2020-01-09 国立大学法人広島大学 経口免疫寛容誘導剤、これを含有する食品および医薬品、ならびに加工食品の製造方法
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CN110408579A (zh) * 2019-06-03 2019-11-05 东北农业大学 牛白细胞介素-2重组乳酸菌及其应用
WO2021061837A1 (en) 2019-09-23 2021-04-01 President And Fellows Of Harvard College Biomaterial-based antigen free vaccine and the use thereof
CA3156035A1 (en) 2019-09-27 2021-04-01 Intrexon Actobiotics Nv D/B/A Precigen Actobio Treatment of celiac disease
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
US11728004B1 (en) 2021-01-28 2023-08-15 Board Of Trustees Of The University Of Alabama Systems and methods for improving radiation tolerance of three-dimensional flash memory
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100495A (en) 1975-11-27 1978-07-11 Cselt - Centro Studi E Laboratori Telecomunicazioni Adaptive method of and means for recovering digital signals
US4190495A (en) 1976-09-27 1980-02-26 Research Corporation Modified microorganisms and method of preparing and using same
US4874702A (en) 1980-09-08 1989-10-17 Biogen, Inc. Vectors and methods for making such vectors and for expressive cloned genes
US4888170A (en) 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
US5417986A (en) 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5032510A (en) 1984-09-26 1991-07-16 Eli Lilly And Company Method for expression and secretion in bacillus
DE3578852D1 (de) 1984-09-26 1990-08-30 Lilly Co Eli Verfahren zur expression und sekretion in bacillus.
US5591632A (en) 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
WO1988006626A1 (en) 1987-03-02 1988-09-07 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US5330753A (en) 1987-04-29 1994-07-19 President And Fellows Of Harvard College Cholera vaccines
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US5972685A (en) 1988-07-21 1999-10-26 Iowa State University Research Foundation, Inc. Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration
IE892131A1 (en) 1989-06-30 1991-01-02 Univ Cork Marker genes for genetic manipulation
US5149532A (en) 1989-11-01 1992-09-22 Cedars Sinai Medical Center Method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms
DE4006521A1 (de) 1990-03-02 1991-09-05 Bayer Ag Zuckerhaltige polymere zur umhuellung und einbettung von arzneistoffen
GB9006400D0 (en) 1990-03-22 1990-05-23 Ciba Geigy Ag Bacterial vectors
IL99097A0 (en) 1990-09-05 1992-07-15 Akzo Nv Haemophilus paragallinarum vaccine
JP3415145B2 (ja) 1991-03-05 2003-06-09 ザ ウエルカム ファウンデーション リミテッド 弱毒化細菌における組換えタンパク質の発現
CA2120626C (en) 1991-10-07 2009-10-06 Douglas Wilmore Method for enhancing gut absorption
IL103530A0 (en) 1991-10-25 1993-03-15 Duphar Int Res Treponema hyodysenteriae vaccine
WO1993017117A1 (en) 1992-02-27 1993-09-02 Lynxvale Limited Heterologous gene expression in lactococcus, and the expression products therefrom
US5455034A (en) 1992-06-26 1995-10-03 Kansas State University Research Foundation Fusobacterium necrophorum leukotoxoid vaccine
DE4231764A1 (de) 1992-09-23 1994-03-24 Inst Pflanzengenetik & Kultur Verfahren zur chromosomalen Integration eines Produkt-Gens
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5691185A (en) 1993-10-08 1997-11-25 Chr. Hansen A/S Lactic acid bacterial suppressor mutants and their use as selective markers and as means of containment in lactic acid bacteria
BR9407813A (pt) 1993-10-13 1997-05-06 Gx Biosystems As Nucleases de staphylococcus recombinantes e seu uso na limitação da sobrevivencia de microorganismos elaborados por engenharia genética
IT1270123B (it) 1994-10-05 1997-04-28 Dompe Spa Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
US5733540A (en) 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
WO1996032486A1 (en) 1995-04-11 1996-10-17 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method for the construction of vectors for lactic acid bacteria like lactobacillus such that the bacteria can efficiently express, secrete and display proteins at the surface
US5753622A (en) 1995-05-10 1998-05-19 University Technologies International, Inc. Use of epidermal growth factor as a gastrointestinal therapeutic agent
JPH11507532A (ja) 1995-06-07 1999-07-06 ワシントン ユニバーシティ 環境に制限される生存能を有する組換え細菌システム
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
GB9518323D0 (en) 1995-09-07 1995-11-08 Steidler Lothar Materials and methods relating to the attachment and display of substances on cell surfaces
GB9521568D0 (en) 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
US5951976A (en) * 1996-03-28 1999-09-14 Whitenead Institute For Biomedical Research Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
WO1997038688A1 (en) 1996-04-12 1997-10-23 Peptide Technology Pty. Limited Methods of treating immunopathologies using polyunsaturated fattyacids
CA2252439C (en) 1996-04-19 2014-09-30 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens
US5972887A (en) 1996-09-19 1999-10-26 The Nemours Foundation Treatment of intestinal epithelial cell malfunctions with Hepatocyte Growth Factor
US5723245A (en) 1996-10-09 1998-03-03 Xerox Corporation Colored toner and developer compositions and process for enlarged color gamut
US7361331B2 (en) * 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
GB9700939D0 (en) 1997-01-17 1997-03-05 Microbial Technics Limited Therapy
US6685943B1 (en) 1997-01-21 2004-02-03 The Texas A&M University System Fibronectin binding protein compositions and methods of use
ES2276448T3 (es) 1997-06-20 2007-06-16 Intervet International Bv Vacuna contra clostridium perfringens.
US6100388A (en) 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
CA2327387C (en) 1998-05-07 2012-07-03 Gx Biosystems A/S Cytotoxin-based biological containment
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
MXPA01003197A (es) 1998-09-28 2004-04-21 Warner Lambert Co Suministro enterico y colonico utilizando capsulas de chpm.
WO2000022909A2 (en) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
DE69914932T2 (de) 1998-10-20 2004-12-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
PT1739178E (pt) 1999-07-05 2010-11-17 Actogenix Nv Libertação de péptidos trifólios
PT1356073E (pt) 2000-10-20 2010-02-15 Bioneer As Método de fermentação aperfeiçoado para a produção de produtos genéticos heterólogos em bactérias do ácido láctico
DK1383897T3 (da) * 2001-05-03 2006-10-30 Vlaams Interuniv Inst Biotech Selv-containing Lactococcus-stamme
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
NO318426B1 (no) 2001-10-02 2005-04-18 Neurozym Biotech As Et materiale for a senke konsentrasjonen av patogene tarmpeptider
EP1319410A1 (en) 2001-12-11 2003-06-18 Société des Produits Nestlé S.A. Use of micro-organisms for a directed delivery of substances to specific parts of the gut
US20040043003A1 (en) 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
DE10208653A1 (de) 2002-02-28 2003-09-18 Medinnova Ges Med Innovationen Mikroorganismus als Träger von Nukleotidsequenzen kodierend für Zellantigene zur Behandlung von Tumoren
US7425449B2 (en) 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
AU2003234634A1 (en) 2002-05-14 2003-12-02 Felix Hausch Drug therapy for celiac sprue
US7776545B2 (en) 2002-11-20 2010-08-17 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for Celiac Sprue
EP1364586A1 (en) * 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
JP2005529622A (ja) 2002-06-19 2005-10-06 ヴェーイーベー・ヴェーゼットウェー 腸吸収を促進するための方法および手段
AU2003298291A1 (en) 2002-11-15 2004-06-15 Universiteit Gent Self-containing lactobacillus strain
JP4589618B2 (ja) * 2003-11-28 2010-12-01 独立行政法人農業生物資源研究所 免疫調節性機能を誘導する乳酸菌類とその成分
EP1725254A4 (en) * 2004-02-04 2008-02-13 Univ Columbia ANTI-CD3 IMMUNOTHERAPY AND SPECIFIC ANTIGENS FOR THE TREATMENT OF AUTOIMMUNITY
CN1695469A (zh) 2005-05-17 2005-11-16 田星 一种风味益生发酵乳及其制作方法
ES2405552T3 (es) 2005-11-29 2013-05-31 Actogenix N.V. Inducción de tolerancia mucosa a antiantígenos de células beta de islotes pancreáticos
WO2008090223A2 (en) 2007-01-25 2008-07-31 Actogenix N.V. Treatment of immune disease by mucosal delivery of antigens using genetically modified lactobacillus

Also Published As

Publication number Publication date
US10195269B2 (en) 2019-02-05
US20140322230A1 (en) 2014-10-30
BRPI0619206A2 (pt) 2011-09-20
JP2013189446A (ja) 2013-09-26
JP2009521406A (ja) 2009-06-04
AU2006319216A1 (en) 2007-06-07
US9539291B2 (en) 2017-01-10
CN101316611B (zh) 2017-05-03
WO2007063075A1 (en) 2007-06-07
US8748126B2 (en) 2014-06-10
EP2119450B1 (en) 2013-02-13
EP1957100B1 (en) 2016-07-13
US20170100475A1 (en) 2017-04-13
ES2405552T3 (es) 2013-05-31
RU2008126198A (ru) 2010-01-10
US20090148389A1 (en) 2009-06-11
JP5410759B2 (ja) 2014-02-05
EP2119450A3 (en) 2010-06-30
EP3097924A1 (en) 2016-11-30
EP2119450A2 (en) 2009-11-18
DK2119450T3 (da) 2013-05-06
CN101316611A (zh) 2008-12-03
RU2420569C2 (ru) 2011-06-10
PT2119450E (pt) 2013-04-26
EP1957100A1 (en) 2008-08-20
US20100172920A1 (en) 2010-07-08
US8398995B2 (en) 2013-03-19
US9526750B2 (en) 2016-12-27
CA2631598C (en) 2017-06-27
CA2631598A1 (en) 2007-06-07
AU2006319216B2 (en) 2012-09-13
EP3097924B1 (en) 2020-01-08
US20140322266A1 (en) 2014-10-30
HK1231371A1 (en) 2017-12-22

Similar Documents

Publication Publication Date Title
ES2596855T3 (es) Inducción de tolerancia mucosa a antígenos
Vandenbroucke et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice
EP3307288B1 (en) Compositions comprising bacterial strains
Wu et al. Immunomodulatory effects of IL-12 secreted by Lactococcus lactis on Th1/Th2 balance in ovalbumin (OVA)-induced asthma model mice
Huang et al. Astragaloside IV attenuates allergic inflammation by regulation Th1/Th2 cytokine and enhancement CD4+ CD25+ Foxp3 T cells in ovalbumin-induced asthma
Chang et al. Alteration of IL-17 related protein expressions in experimental autoimmune myocarditis and inhibition of IL-17 by IL-10-Ig fusion gene transfer
JP2006525313A (ja) 視床下部−脳下垂体−副腎軸過敏性により特徴付けられる非定型うつ病及び他の疾患の治療のプロバイオティック
KR101291960B1 (ko) 장내세균에 의한 생물학적 활성제의 제어된 생산 및 전달
Yang et al. Construction and immunological evaluation of recombinant Lactobacillus plantarum expressing SO7 of Eimeria tenella fusion DC-targeting peptide
CA2932488A1 (en) Bacterial influence on regulation of appetite via clpb protein mimicry of alpha-msh
RU2665848C2 (ru) Иммуногенная лекарственная композиция для медицинского использования, содержащая рекомбинант живой бцж, выделяющий антигены метапневмовируса (hmpv) в суспензию, приготовленную из лиофилизата без добавления адъюванта
CN102573897A (zh) 使用副粘病毒载体的经鼻喷雾型结核疫苗
Wang et al. Allergen specific immunotherapy enhanced defense against bacteria via TGF-β1-induced CYP27B1 in asthma
Guo et al. The construction and immunoadjuvant activities of the oral interleukin-17B expressed by lactobacillus plantarum NC8 strain in the infectious bronchitis virus vaccination of chickens
Chen et al. A bovine whey protein extract can induce the generation of regulatory T cells and shows potential to alleviate asthma symptoms in a murine asthma model
ES2924990T3 (es) Inducción de tolerancia específica de antígeno
Xiong et al. IL-27 overexpression alleviates inflammatory response in allergic asthma by inhibiting Th9 differentiation and regulating Th1/Th2 balance
Tazaki et al. Allergen rush immunotherapy increases interleukin (IL)-12 production and IL-12 receptor β2 chain expression in patients with allergic asthma
Ming et al. Inactivated Mycobacterium phlei inhalation ameliorates allergic asthma through modulating the balance of CD4+ CD25+ regulatory T and Th17 cells in mice
Xu et al. Intranasal administration of recombinant mycobacterium smegmatis inducing IL-17A autoantibody attenuates airway inflammation in a murine model of allergic asthma
CN108697784A (zh) 用于对屋尘螨来源的过敏原的超敏反应的免疫调节剂
JP2016521567A (ja) 半生呼吸器合胞体ウイルスワクチン
TWI850940B (zh) 重組乳酸菌及其用於同時治療及/或預防塵蟎及蟑螂過敏症之用途
CN104107427B (zh) 一种促凋亡重组卡介苗及其制备方法
Liu et al. Oral and intranasal administration of somatostatin DNA vaccine mediated by attenuated SalmonellaEnterica Serovar Typhimurium to promote growth of piglets